Edition:
United Kingdom

People: Ascendis Pharma A/S (ASND.OQ)

ASND.OQ on NASDAQ Stock Exchange Global Select Market

128.96USD
24 May 2019
Change (% chg)

$4.31 (+3.46%)
Prev Close
$124.65
Open
$125.09
Day's High
$129.64
Day's Low
$125.09
Volume
68,746
Avg. Vol
94,459
52-wk High
$131.69
52-wk Low
$53.29

Wolff Jensen, Michael 

Mr. Michael Wolff Jensen, L.L.M. has served as Chairman of the Board of Directors at Ascendis Pharma A/S since January 2008 and as Senior Vice President, General Counsel since June 2013. In addition, Mr. Jensen served as Acting Chief Financial Officer from May 2008 to June 2013. From October 2010 to June 2013, Mr. Jensen served as Senior Legal Advisor and Head of Partnerships (France) for the renewable business division of Dong Energy A/S, the Danish State-owned utility company. Prior to Ascendis Pharma, Mr. Jensen served as Executive Vice President & Chief Financial Officer of Veloxis Pharmaceuticals A/S, a publicly traded biotechnology company, from 2003 to 2008. Prior to joining Veloxis, Mr. Jensen served as Senior Vice President & Chief Financial Officer of Genmab A/S, a publicly traded biotechnology company from 2000 to 2003. Mr. Jensen also currently serves as Chairman of the board of directors of two biotechnology companies; one publicly traded, Eurocine Vaccines AB, and one privately held. Mr. Jensen received an L.L.M. degree from the University of Copenhagen.

Basic Compensation

Total Annual Compensation, --
Restricted Stock Award, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --